Literature DB >> 28430710

Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.

Smiljana Ristić1, Nada Starčević Čizmarević, Polona Lavtar, Luca Lovrečić, Olivio Perković, Juraj Sepčić, Saša Šega Jazbec, Miljenko Kapović, Borut Peterlin.   

Abstract

We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073; odds ratio: 2.64; 95% confidence interval: 0.91-7.60) and a significantly higher frequency of the D allele (P=0.022; odds ratio: 2.43; 95% confidence interval: 1.13-5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men (β=0.371; multiple R change: 0.132; P=0.009) and a higher pretreatment relapse rate in both men (β=-0.438; multiple R change: 0.135; P=0.015) and women (β=-0.208; multiple R change: 0.042; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28430710     DOI: 10.1097/FPC.0000000000000283

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  2 in total

Review 1.  Pharmacogenomics of Multiple Sclerosis: A Systematic Review.

Authors:  Keli Hočevar; Smiljana Ristić; Borut Peterlin
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

2.  Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions?

Authors:  Sanja Dević Pavlić; Sergej Nadalin; Nada Starčević Čizmarević; Alena Buretić-Tomljanović; Anđelka Radojčić Badovinac; Smiljana Ristić
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Jul-Sep       Impact factor: 1.636

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.